Pfizer to buy eczema drugmaker Anacor for $5.2 billion

Pharmaceutical giant makes move in wake of failed Allergan bid

16th May, 2016

Pfizer has agreed to buy Anacor Pharmaceuticals for $5.2 billion – gaining control of an experimental treatment for eczema in its first deal since walking away from a $160 billion takeover of Allergan.

Pfizer will pay $99.25 in cash for each Anacor share, the companies said in a statement today. The transaction, which represents about a 55 per cent premium to Friday’s closing price, is scheduled to be completed in the third quarter and may start adding...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Nadine O’Regan: Fresh female voices seize their moment

Emer McLysaght: How WhatsApp has given gossip a new lease of life

Columnists Emer McLysaght 18 hours ago

James McDermott: The grounds for our world sporting bids would not inspire confidence

Sport James McDermott 18 hours ago

Cathal Mac Coille: Like it or not, the Northern Ireland protocol is the only realistic option

Brexit Cathal Mac Coille 18 hours ago